Cleveland BioLabs Announces Expansion of Entolimod Patent Portfolio With New Composition of Matter Patents

BUFFALO, NY--(Marketwired - Feb 11, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the issuance of several new patents for entolimod in the U.S. and other countries, further strengthening its patent position.

Cleveland BioLabs, Inc. recently secured two composition of matter patents in the U.S., Patent Numbers 8,871,215 and 8,932,609, that cover the Company's lead agent, the flagellin-derived entolimod, as well as various other flagellin-derived agents, for any use, including the biodefense indications that CBLI is pursuing. Further, another new U.S. patent issuance, Patent Number 8,784,840, expands the Company's coverage for using any flagellin agent to treat apoptosis related to radiation exposure.

CBLI now has more than 10 issued or allowed U.S. patents covering compositions of matter and methods of use claims relating to entolimod's biodefense indication, as well as chemotherapy adjuvant and reperfusion injury indications. Additional pending U.S. patent claims include those covering oncology methods of use and other biodefense uses. 

Patents covering methods of protecting against radiation using flagellin, as well as other uses of entolimod, were also issued in various foreign jurisdictions, including Europe, Japan, South Korea, China, Pakistan, Canada, and Eurasia, bringing the number of issued global patents covering composition of matter and uses of entolimod to over 50.

Yakov Kogan, Ph.D., Chief Executive Officer of Cleveland BioLabs commented, "Protection of our novel discoveries surrounding entolimod and its varied applications has long been a corporate priority. We believe that our strong patent portfolio positions us well for future commercialization of entolimod's biodefense indication in the U.S. and abroad, as well as partnering."

About Cleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are entolimod, which is being developed as radiation countermeasure and a potential cancer treatment, and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.

This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words and phrases such as "pending," "believe," "positions us," "future," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to successfully submit and receive approval of our pre-EUA application for entolimod, the conduct and results of our various clinical trials; our ability to obtain approval from the U.S. Food and Drug Administration of our product candidates; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. 

These risks and uncertainties include, among others, our ability to obtain, maintain and protect intellectual property rights (including for entolimod and other pipeline candidates) the Company's failure to successfully and timely develop existing and new products; the Company's collaborative relationships and the financial risks related thereto; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's ability to comply with its obligations under license agreements; the Company's inability to obtain regulatory approval in a timely manner or at all; subsequent changes in the agreement with the Russian Ministry of Industry and Trade, the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.